Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I

Bio2RDF uri

Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I

http://bio2rdf.org/clinicaltrials:NCT00912925

Bio2RDF identifier

NCT00912925

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00912925

http://www.w3.org/2001/XMLSchema#string

brief summary [clinicaltrials_vocabulary:brief-summary]

This study is being con ...... treatment in MPS I patients

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I

http://www.w3.org/2001/XMLSchema#string

clinical result [clinicaltrials_vocabulary:clinical-result]

clinical results for clinicaltrials:NCT00912925 [clinicaltrials_resource:0b2ba230598ec83b904dca8864e7c4f5]

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Overall Change From Baseline to Week 26 in Percent Predicted Forced Vital Capacity (FVC) Baseline to Week 26 [clinicaltrials_resource:0c53028e2ebd39c02c5ee95a165410ef]

Overall Change From Baseline to Week 26 in Percent Predicted Forced Vital Capacity (FVC) Baseline to Week 26 [clinicaltrials_resource:bdfbfaeb9a11945a60bebd1be8ccdb54]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Overall Change From Baseline to Week 26 in Percent Predicted Forced Vital Capacity (FVC) Baseline to Week 26 [clinicaltrials_resource:0f47ce1c2cf300829eccb50540371ee2]

Overall Change From Baseline to Week 26 in Percent Predicted Forced Vital Capacity (FVC) Baseline to Week 26 [clinicaltrials_resource:86c39037807cebd5066e754a6e7c8b6e]

Overall Change From Baseline to Week 26 in Percent Predicted Forced Vital Capacity (FVC) Baseline to Week 26 [clinicaltrials_resource:92e95f4a43359cf602eee26509772e22]

Overall Change From Baseline to Week 26 in Percent Predicted Forced Vital Capacity (FVC) Baseline to Week 26 [clinicaltrials_resource:d1a60abb25e96eb4a1a01defa1c81bc3]

Overall Change From Baseline to Week 26 in Percent Predicted Forced Vital Capacity (FVC) Baseline to Week 26 [clinicaltrials_resource:eaf8b90346a147d9cdb8efec4b593f67]

collaborator [clinicaltrials_vocabulary:collaborator]

Genzyme, a Sanofi Company [clinicaltrials_resource:8c6e8d6b8a19ceb3967bff4897da3764]

completion date [clinicaltrials_vocabulary:completion-date]

2001-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

condition [clinicaltrials_vocabulary:condition]

Hurler-Scheie Syndrome [clinicaltrials_resource:3285825654ba4c812b7d1b80bbcdf1ad]

Mucopolysaccharidosis I [clinicaltrials_resource:3f6aa4e6287fb5bf722f1a3a2a4c5f0e]

Hurlers Syndrome [clinicaltrials_resource:b09e85589febd0366b05043b5d0f6161]

condition browse [clinicaltrials_vocabulary:condition-browse]

Mucopolysaccharidosis I [clinicaltrials_resource:3f6aa4e6287fb5bf722f1a3a2a4c5f0e]

Syndrome [clinicaltrials_resource:48d8d6f5a3efbf52837d6b788a22859a]

Mucopolysaccharidoses [clinicaltrials_resource:756327df5c81fdf20eadc33d0740d1c6]

condition mesh [clinicaltrials_vocabulary:condition-mesh]

Mucopolysaccharidosis I [clinicaltrials_resource:3f6aa4e6287fb5bf722f1a3a2a4c5f0e]

Syndrome [clinicaltrials_resource:48d8d6f5a3efbf52837d6b788a22859a]

Mucopolysaccharidoses [clinicaltrials_resource:756327df5c81fdf20eadc33d0740d1c6]

country [clinicaltrials_vocabulary:country]

United States [clinicaltrials_resource:f253efe302d32ab264a76e0ce65be769]

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00912925 [clinicaltrials_resource:33652a55bb8cb03ac3c5d3d59609ed08]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2009-06-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

firstreceived results date [clinicaltrials_vocabulary:firstreceived-results-date]

2009-07-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

rhIDU (recombinant human-Alpha-L-Iduronidase) [clinicaltrials_resource:e1c1d726f1063f3e1f52db4cea059f59]

Placebo [clinicaltrials_resource:fd43a16763d462376cec56cb18ff6117]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

Yes

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-03-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Genzyme, a Sanofi Company [clinicaltrials_resource:8c6e8d6b8a19ceb3967bff4897da3764]

location [clinicaltrials_vocabulary:location]

New York University [clinicaltrials_resource:308e5706909b44ad75a97b878aa92fe8]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00912925

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

A Randomized, Double-Blind, Pl ...... s With Mucopolysaccharidosis I

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

ALID-003-99

http://www.w3.org/2001/XMLSchema#string

outcome [clinicaltrials_vocabulary:outcome]

Overall Change From Baseline to Week 26 in Percent Predicted Forced Vital Capacity (FVC) [clinicaltrials_resource:NCT00912925/outcome/1]

overall official [clinicaltrials_vocabulary:overall-official]

Medical Monitor [clinicaltrials_resource:7c18913076d441546a167cc2fc7a1dfa]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:5235e9756b34cfabf40e7bc74391ab70]

participant flow [clinicaltrials_vocabulary:participant-flow]

participant flow for clinicaltrials:NCT00912925 [clinicaltrials_resource:69c9ffbe83fe3918c65786c4fe02233d]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2001-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

reported events [clinicaltrials_vocabulary:reported-events]

Reported events for NCT00912925 [clinicaltrials_resource:e9fce2bdc37f0787f3d4bdf1ec4214e6]

responsible party [clinicaltrials_vocabulary:responsible-party]

Medical Monitor, Genzyme Corporation [clinicaltrials_resource:a37317b1d61c1b7de15a5d9064c62422]

source [clinicaltrials_vocabulary:source]

Sanofi [clinicaltrials_resource:26fba9456e1e33d5671ff7055ed23621]

start date [clinicaltrials_vocabulary:start-date]

2000-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00912925 study design [clinicaltrials_resource:897f3fbedd928527a28db1c775f8b692]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00912925

verification date [clinicaltrials_vocabulary:verification-date]

2015-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00912925

http://www.w3.org/2001/XMLSchema#string